<DOC>
	<DOCNO>NCT01060059</DOCNO>
	<brief_summary>Although efficacy safety profile exenatide well establish , data exist real world result exenatide treatment specific population clinical setting . This study intend fill gap observe collect prospective data population Italian patient initiate treatment either exenatide basal insulin formulation failure achieve glycemic control oral antihyperglycemic agent ( OHA ) . Observational study represent noninterventional research ; therefore , study involve randomization patient particular comparator arm therapy . The term `` noninterventional '' mean healthcare provider decision regard proper treatment care patient make course normal clinical practice . Patients enrol study enrol collection data observation make normal clinical practice .</brief_summary>
	<brief_title>Exenatide Basal Insulins Use Real Setting : Observational Study Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1 . Are inadequately control single multiple OHA evidence HbA1c &gt; 7.0 % 2 . Have present routine course care , together physician , decide initiate treatment either exenatide twice daily conventional insulin therapy basal insulin ( insulin glargine , detemir , protaminated insulin lispro , protaminated human insulin ) add exist treatment OHA 3 . Have treat GLP1 receptor agonist 7 consecutive day within 3 month enter study 4 . Have treat insulin 7 consecutive day within last 3 month 3 month course disease 5 . Are simultaneously participate another study include investigational drug procedure study entry 6 . Have fully inform give write consent use data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes ; exenatide ; Byetta ; basal insulin ; Amylin ; Lilly</keyword>
</DOC>